Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles by Davis, N. L. et al.
JOURNAL OF VIROLOGY,
0022-538X/00/$04.0010
Jan. 2000, p. 371–378 Vol. 74, No. 1
Copyright © 2000, American Society for Microbiology. All Rights Reserved.
Vaccination of Macaques against Pathogenic Simian
Immunodeficiency Virus with Venezuelan Equine Encephalitis
Virus Replicon Particles
NANCY L. DAVIS,1* IAN J. CALEY,1 KEVIN W. BROWN,1 MICHAEL R. BETTS,1†
DAVID M. IRLBECK,1 KATHRYN M. MCGRATH,2 MARY J. CONNELL,3 DAVID C. MONTEFIORI,4
JEFFREY A. FRELINGER,1 RONALD SWANSTROM,1,5 PHILIP R. JOHNSON,3
AND ROBERT E. JOHNSTON1
Department of Microbiology and Immunology,1 Curriculum in Genetics and Molecular Biology,2 and University of
North Carolina Center for AIDS Research5, University of North Carolina, Chapel Hill, North Carolina 27599;
Children’s Hospital and Department of Medical Microbiology and Immunology, The Ohio State University,
Columbus, Ohio 432053; and Department of Surgery, Duke University Medical Center,
Durham, North Carolina 277104
Received 1 July 1999/Accepted 1 October 1999
Vaccine vectors derived from Venezuelan equine encephalitis virus (VEE) that expressed simian immuno-
deficiency virus (SIV) immunogens were tested in rhesus macaques as part of the effort to design a safe and
effective vaccine for human immunodeficiency virus. Immunization with VEE replicon particles induced both
humoral and cellular immune responses. Four of four vaccinated animals were protected against disease for
at least 16 months following intravenous challenge with a pathogenic SIV swarm, while two of four controls
required euthanasia at 10 and 11 weeks. Vaccination reduced the mean peak viral load 100-fold. The plasma
viral load was reduced to below the limit of detection (1,500 genome copies/ml) in one vaccinated animal
between 6 and 16 weeks postchallenge and in another from week 6 through the last sampling time (40 weeks
postchallenge). The extent of reduction in challenge virus replication was directly correlated with the strength
of the immune response induced by the vectors, which suggests that vaccination was effective.
The solution to the worldwide human immunodeficiency
virus (HIV) epidemic will include an affordable, safe, and
effective vaccine. However, safety concerns surround the de-
velopment of live, attenuated, or whole killed vaccines (3, 13,
44), and recombinant protein vaccination has been only mod-
erately immunogenic in humans (14). One strategy for balanc-
ing safety and immunogenicity is the use of virus vectors, vi-
ruses whose genomes have been engineered to express
heterologous proteins. When used for vaccination, a virus vec-
tor targets specific cells in the host for in vivo production of
immunogens. In the best case, this results in induction of pro-
tective immunity against the pathogen whose genes were in-
serted into the vector. The most widely studied virus vectors
are recombinant poxviruses, and the HIV-specific immune re-
sponse generated in human subjects by highly attenuated pox-
virus vectors is currently under investigation (12, 17, 41). The
addition of purified recombinant protein boosts strengthened
the immune response, both in monkey trials and in human
trials of candidate AIDS vaccines (12, 17, 27, 28, 41). Extensive
experimentation in animal models with these vector systems,
and several others, is proceeding with the goal of developing a
compelling strategy for an effective HIV vaccine (1, 2).
Expression vectors also have been derived from three alpha-
viruses: Sindbis virus, Semliki Forest virus (SFV), and Vene-
zuelan equine encephalitis virus (VEE) (16, 33, 47). Two gen-
eral types of alphavirus vectors have been shown to induce
immune responses to heterologous proteins in rodent models.
These are (i) propagation-competent double-promoter vectors
that express a foreign gene from a second viral subgenomic
RNA promoter (16, 21) and (ii) single-hit nonpropagating
replicon vectors that contain a foreign gene in place of the viral
structural protein genes (22, 42, 43, 48, 49). The advantages of
replicon vectors include increased capacity for foreign se-
quence, lack of reactogenicity, and reduction of anti-vector
immune responses.
Replicon vectors derived from VEE (43) have properties
that may be advantageous for an HIV vaccine. First, VEE
replicon particles (VRP) target expression to lymphoid tissues,
a preferred site for induction of immunity. The specific cell
types infected in the lymph node draining the site of subcuta-
neous (s.c.) inoculation of mice vary with mutations in the
glycoprotein genes. In the context of the parental glycopro-
teins, or of glycoprotein mutants at higher doses, a major
target appears to be dendritic cells (35a). Targeting of VRP to
a professional antigen-presenting cell (4) may be of vital im-
portance for HIV proteins with low intrinsic immunogenicity.
Second, s.c. inoculation of mice with VRP expressing the hem-
agglutinin (HA) protein of influenza virus (HA-VRP) gives
complete protection against a lethal intranasal challenge with
influenza virus (43). The immunity induced is sufficient to
block challenge virus replication at the level of the mucosal
target, the respiratory epithelium (N. L. Davis, K. W. Brown,
and R. E. Johnston, unpublished results). The ability to protect
against a mucosal challenge following s.c. immunization is
characteristic of both the live, attenuated VEE vaccine (TC-
83) that has been administered to thousands of people for
protection against VEE infection and more recent VEE vac-
cine candidates (9, 15, 29, 31). Because protection of mucosal
surfaces from sexually transmitted HIV will be required of an
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effective vaccine, the potential to protect mucosal surfaces is a
key feature of VEE vaccine vectors. Third, VEE vectors pro-
duce high levels of authentic foreign proteins, including non-
glycosylated and glycosylated proteins, without a requirement
for a translational enhancer downstream of the AUG start
codon as in other alphavirus vectors (18). The amount of
protein produced by VEE vectors is comparable to that of
baculovirus (35) and vaccinia virus vectors (36).
Redundant safety features have been engineered into the
VEE replicon vectors. Replicon RNA is packaged into VRP by
structural proteins provided in trans from two distinct helper
RNAs in baby hamster kidney (BHK) cells cotransfected with
all three RNAs (43). The use of two helper RNAs instead of
one reduces the generation of viable virus by at least a factor
of 105. The insertion of two independently attenuating muta-
tions in the glycoprotein genes ensures that even a rare recom-
binant would be a nonpathogenic vaccine strain. More than
1,000 rodents, a very sensitive host for VEE, and 64 macaques
have been given primary doses as high as 108 IU of VRP with
no detectable clinical signs. Since the macaque model reflects
human experience with VEE and VEE vaccines, this record
suggests that trials of VRP vaccines for HIV in humans would
demonstrate them to be safe (38) (J. F. Smith, N. L. Davis, and
R. E. Johnston, unpublished results).
In primates, the efficacy of VRP vaccination has been dem-
onstrated dramatically with VRP expressing the glycoprotein
(GP) of Marburg virus, a filovirus closely related to Ebola
virus. GP-VRP-vaccinated cynomolgus macaques were com-
pletely protected against a lethal challenge with Marburg virus
and had no detectable viremia, while controls died within 10
days, with serum titers of 107 to 108 PFU of the challenge virus
(22). Primate trials also have been performed with replicon
vectors derived from SFV with a lentivirus challenge. In the
first test, pigtailed macaques were vaccinated with SFV repli-
con particles expressing gp160 from the acutely fatal simian
immunodeficiency virus (SIV) sooty mangabey (sm) strain
PBj14 and challenged with a 75% fatal dose of SIVsm PBj14
virus (40). Vaccinated animals were protected against fatal
acute disease. In a second study, cynomolgus macaques were
vaccinated with SFV replicon particles expressing gp160 from
the IIIB strain of HIV type 1 (HIV-1IIIB) and challenged with
a 100% infectious dose of simian-human immunodeficiency
virus 4 (6). Vaccinated animals were not protected against
infection but showed some reduction in viral load.
In contrast to previous studies with SFV-derived replicon
vaccines, the first test of VEE-based antilentivirus vaccines in
primates, reported here, included challenge with a highly
pathogenic strain of SIV that consistently induces lethal im-
munodeficiency in rhesus macaques. Macaques received VRP
expressing proteins encoded in the SIVsm H-4i molecular
clone, which is closely related to the pathogenic uncloned
SIVsm E660 (19, 23, 26). Humoral and cellular immune re-
sponses to vaccination were measured, and animals were chal-
lenged intravenously (i.v.) with SIVsm E660 (grown in ma-
caque peripheral blood mononuclear cells [PBMCs]). This
pathogenic challenge virus contains a more genetically diverse
population than virus derived from the SIVsm H-4i molecular
clone and was therefore a more rigorous challenge than the
homologous SIVsm H-4i.
The infection of rhesus macaques with SIV is currently one
of the best animal models for HIV infection of humans. Al-
though utilization of virus vectors to protect against infection
with highly pathogenic strains of SIV has proven difficult, there
are encouraging data to suggest that protection against disease
may be attainable (1, 24). Our goal was to correlate the relative
strength of the immune response in vaccinated animals with
the level of protection against a pathogenic high-dose SIV
challenge. The effectiveness of SIV-VRP vaccination was eval-
uated in terms of mortality, peak plasma viremia, and ability to
control virus replication (i.e., plasma viremia set point).
MATERIALS AND METHODS
Cells and plasmids. BHK cells were obtained from the American Type Cul-
ture Collection in passage 52 or 53 and were used between passages 54 and 64.
Cells were maintained in alpha minimal essential medium containing 10% donor
calf serum, 10% tryptose phosphate broth, and 0.29 mg of L-glutamine per ml.
For electroporation, cells were cultured overnight in medium containing 10%
fetal calf serum, harvested when subconfluent, and prepared for electroporation
as previously described (33).
SIV genes were inserted into the VEE replicon plasmid pVR2 (43) as follows.
PCRs with the SIVsm H-4i plasmid as the template and appropriate primers
were used to amplify (i) the region of gag encoding matrix-capsid (MA/CA;
nucleotides 1049 to 2143, numbering from the 59 end of the SIVsm H-4i genome)
with a change in codon 2 from Gly to Ala to ablate the myristylation signal, (ii)
the entire env open reading frame (gp160; nucleotides 6587 to 9244), and (iii) env
lacking the 39 region encoding the membrane-spanning domain and the cyto-
plasmic tail (gp140; nucleotides 6587 to 8626). Amplified regions were initially
cloned into PCR cloning plasmids, and products were confirmed by sequencing.
Flanking ClaI restriction sites contained in the primers were used to subclone gag
sequences directly into pVR2. Flanking SalI restriction sites contained in the
primers were used for insertion of env sequences into a shuttle plasmid contain-
ing a copy of the VEE subgenomic 26S mRNA promoter followed by a multiple
cloning site and the VEE 39 untranslated region. The resulting 26S transcription
unit was moved into pVR2 by using unique restriction sites and standard tech-
niques.
These derivatives of pVR2 containing specific SIVsm H-4i sequences were
used for in vitro transcription of VEE replicon RNA. Plasmids pV3014D520-
7505D8495-11229 and pV3014D520-7505D7565-8386 were transcribed in vitro to
give capsid helper RNA and glycoprotein helper RNA, respectively (43). Two
independently attenuating mutations are contained in the genes expressed from
the glycoprotein helper: a change from Glu to Lys at E2 position 209 and a
change from Ala to Thr at E1 position 272 (20).
Production and titration of VRP. BHK cells electroporated with a mixture of
replicon RNA, capsid helper RNA, and glycoprotein helper RNA, transcribed
and capped in vitro, were diluted into growth medium in a 75-cm tissue culture
flask and incubated at 37°C under 5% CO2 for 24 to 27 h. VRP-containing
culture supernatants were clarified by centrifugation at 12,000 3 g for 30 min.
VRP were partially purified and concentrated by sedimentation at 72,000 3 g for
4 h through a 5-ml cushion of 20% (wt/vol) sucrose dissolved in 0.0017 M
KH2PO4–0.005 M Na2PO4–0.15 M NaCl (pH 7.4) (phosphate-buffered saline
[PBS]), followed by overnight resuspension in PBS at 4°C. For titration of VRP,
BHK cells were infected with serial dilutions of concentrated VRP for 16 h at
37°C, fixed in methanol for 10 min at 4°C, and incubated sequentially with
SIV-infected macaque serum, biotinylated anti-human immunoglobulin G (IgG),
and avidin conjugated to fluorescein isothiocyanate (FITC). Single replicon-
infected cells were scored microscopically by fluorescence under UV illumina-
tion.
Radioimmunoprecipitation and polyacrylamide gel electrophoresis. BHK
cells that had been either infected with VRP or mock infected were incubated in
methionine-free medium for 4 h between 6 and 10 h postinfection and then in
medium containing 20 mCi of [35S]methionine/ml for 2 h between 10 and 12 h
postinfection. At 12 h postinfection cytoplasmic extracts were prepared in the
presence of protease inhibitors and then were immunoprecipitated with either
SIV-infected monkey serum or normal monkey serum by using protein A-Sepha-
rose CL-4B (Sigma) (30). Proteins were resolved by electrophoresis in 10%
polyacrylamide gels containing 0.1% (wt/vol) sodium dodecyl sulfate (SDS) after
denaturation in 1% SDS and 50 mM 2-mercaptoethanol were compared to
molecular weight standards (14.3 to 220 kDa; Amersham Pharmacia Biotech).
Vaccination protocols. Four macaques were inoculated s.c. in the inguinal area
at week 0 with 105 IU each of SIV gp160-VRP and SIV MA/CA-VRP, boosted
by the same route at week 7 with 107 IU of each VRP, and boosted i.v. at weeks
12 and 20 with 5 3 108 IU of each VRP. Two control animals were inoculated
with equivalent doses of HA-VRP, and two were inoculated with diluent. The
four SIV-VRP-immunized monkeys received an additional dose of 2 3 107 IU of
gp140-VRP s.c. in the arm at week 41, followed by a final boost of 2 3 107 IU
each of gp140-VRP and MA/CA-VRP s.c. in the arm at week 49. All animal care
was in accordance with institutional guidelines.
Quantitation of anti-SIV antibody by ELISA. The antigen used for enzyme-
linked immunosorbent assay (ELISA) was a six-His-tagged version of SIVsm
H-4i gp140 secreted from BHK cells infected with six-His-tagged gp140-VRP
and purified over a Ni-nitrilotriacetic acid (NTA) matrix (Qiagen). Antigen
dissolved in carbonate buffer (15 mM Na2CO3–34.8 mM NaHCO3 [pH 9.6]) was
bound to microtiter plates (Immulon-4; Dynatech Laboratories, Inc.) by incuba-
tion at 37°C for 1 h. Serum dilutions in duplicate were incubated with the
antigen, and bound antibody was quantitated with horseradish peroxidase
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(HRP)-linked anti-monkey IgG (Cappel) as the secondary antibody. Titers rep-
resent the highest serum dilution that gave an optical density at 450 nm of $0.2.
Cytotoxic T-lymphocyte (CTL) assay. PBMCs collected from vaccinated and
control macaques were cultured in vitro with autologous herpesvirus papio-
transformed B lymphocytes infected with vaccinia virus vectors expressing SIV
Gag-Pro-Pol and SIV Env in the presence of interleukin 2 (IL-2) and IL-7 for 7
to 8 days. PBMCs from HA-VRP or diluent controls did not grow when cultured
under these conditions of in vitro stimulation. Following positive selection of
CD81 cells by using magnetic beads (Miltenyi Biotec), chromium release assays
were performed against autologous B lymphocytes infected with vaccinia virus
vectors expressing either SIV Gag-Pro-Pol or SIV Env by published methods
(37). Control targets were infected with a wild-type vaccinia virus vector or left
uninfected. The percent specific lysis was calculated according to the following
formula: (experimental lysis 2 spontaneous lysis)/(maximal lysis 2 spontaneous
lysis) 3 100.
RESULTS
Expression of SIV genes from SIV-VRP vectors. The region
of the gag gene encoding the matrix and capsid polypeptides
(MA/CA), the env gene, and a derivative of env (lacking the
region encoding its membrane-spanning and cytoplasmic por-
tions) of the molecular clone SIVsm H-4i were individually
inserted into VEE replicon plasmids. Individual VRP prepa-
rations expressing each of these SIV sequences (MA/CA-VRP,
gp160-VRP, and gp140-VRP, respectively) were prepared as
previously described (43), and expression in VRP-infected cell
cultures was examined (Fig. 1). Proteins of the expected size
and antibody reactivity were expressed in all three cases. The
size and amount of MA/CA protein was estimated by compar-
ison to molecular weight markers and to a known quantity of
purified six-His-tagged SIV MA/CA protein synthesized in
Escherichia coli. The apparent molecular size of MA/CA was
42 kDa, and the approximate intracellular level of MA/CA was
60 mg per 107 cells (9 3 107 copies per cell) at 26 h after
infection (Fig. 1A). The amount of gp140 was estimated by
comparing the Western blot reactivity with SIV-infected mon-
key serum to that of a known quantity of SIVmac239 rgp130
standard protein produced in vaccinia virus vector-infected
Chinese hamster ovary cells (Quality Biological, Inc.). About
0.5 mg of gp140 was secreted per 107 cells during a 12-h infec-
tion (Fig. 1C). These amounts are consistent with levels of
heterologous protein production in VRP-infected cells re-
ported earlier (43). gp140 was secreted in an oligomeric form,
as shown by gradient centrifugation and chemical cross-linking
studies (I. J. Caley, K. W. Brown, and R. E. Johnston, unpub-
lished results). gp160 accumulated in much lower amounts,
possibly due to toxic effects or turnover of this protein in
gp160-VRP-infected cells.
Vaccination of macaques with an SIV-VRP vector cocktail:
humoral immune response. A cocktail of SIV MA/CA-VRP
and gp160-VRP was used to vaccinate four juvenile rhesus
macaques (Macaca mulatta) in an initial series of four inocu-
lations by two different routes (Fig. 2). Two control animals
received equivalent doses of HA-VRP, and two received di-
luent. The first two inoculations, administered s.c. in the in-
guinal area, were designed for efficient delivery of the VRP
vaccine to the inguinal lymph nodes. The third and fourth
inoculations, administered i.v. at a high dose, were designed to
direct the VRP to as many lymphoid tissues as possible. That
a sufficient amount of VRP had reached these tissues by the
third inoculation was indicated by the response to VRP ex-
pressing HA, a viral protein that is immunogenic in primates
(11). Following the third inoculation, the two HA-VRP control
monkeys had anti-influenza serum IgG titers of 16,000 and
8,000 by ELISA and hemagglutination inhibition titers (80 and
160) equivalent to those that are protective in humans (10). It
was more difficult to elicit a detectable humoral response to
the SIV proteins (Fig. 2). After four inoculations, two of four
vaccinated animals showed reactivity to SIV envelope protein
by ELISA, and one had detectable levels of neutralizing anti-
body against virus generated from the SIVsm H-4i molecular
clone.
We reasoned that the production of large amounts of the
secreted, oligomeric form of the envelope protein within the
lymph node might be a more efficient inducer of anti-Env
antibody. Therefore, additional immunizations used gp140-
VRP. The fifth inoculation was gp140-VRP alone and the sixth
was a cocktail of gp140-VRP and MA/CA-VRP, both given by
a third route, s.c. in the arm. The choice of a subcutaneous
route was based on the recent identification of Langerhans’
cells as a primary target of VEE infection (35a). The fifth
immunization resulted in a boost in anti-Env IgG (Fig. 2A) and
anti-SIVsm H-4i neutralizing titer (Fig. 2B) in three of four
vaccinated animals. The final immunization did not have a
dramatic effect but did increase the anti-Env ELISA titer of
the lowest responder.
It should be noted that no clinical side effects of VRP vac-
cination were seen in any individual at any time during any of
the vaccination regimens.
The antibody responses to VEE, measured following each
immunization, were below the level of detection after the first
two s.c. inoculations. This was expected, since the mass of
FIG. 1. Expression of SIV proteins in VRP-infected cultured cells. (A) BHK
cells were mock infected (lane 1) or infected with SIV MA/CA-VRP at a mul-
tiplicity of infection (MOI, infectious units [IU] per cell) of 5 (lane 2), and 26 h
later cytoplasmic extracts were prepared. Proteins resolved by SDS-polyacryl-
amide gel electrophoresis were visualized by staining with Coomassie brilliant
blue (8). Samples each contained 3 3 105 cell equivalents. The MA/CA band
(arrowhead) migrated in the region of a coelectrophoresed six-His-tagged SIV
MA/CA standard synthesized in E. coli. The intensities of the bands given by
0.825 mg of the standard and by the MA/CA-VRP-infected cell lysate were
compared by using densitometry to estimate the amount of MA/CA produced.
(B) BHK cells were infected with SIV gp140-VRP at an MOI of 4 (lanes 1 and
2) or with SIV gp160-VRP at an MOI of 4 (lanes 3 and 4) or were mock infected
(lanes 5 and 6). [35S]methionine-labeled samples (8 3 106 cell equivalents) were
immunoprecipitated with either SIV-infected monkey serum (lanes 1, 3, and 5)
or normal monkey serum (lanes 2, 4, and 6). Proteins were visualized by auto-
radiography, and molecular weight standards were used to identify gp160 and
gp140 bands (arrowheads). (C) Culture supernatants (from cells described in the
legend to panel B) from the gp140-VRP-infected cells (lanes 1 and 2) or gp160-
VRP-infected cells (lanes 3 and 4) were collected, concentrated, immunopre-
cipitated with either SIV-infected monkey serum (lanes 1 and 3) or uninfected
monkey serum (lanes 2 and 4), and subjected to SDS-polyacrylamide gel elec-
trophoresis. Samples each contained supernatant protein secreted from 8 3 106
cells, less any protein lost during the concentration process. The fully glycosy-
lated gp140 band is marked with an arrowhead.
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particles inoculated was small and the vector does not produce
VEE structural proteins. However, VEE-specific antibody be-
gan to appear after the first i.v. inoculation. Serum samples
taken 3 weeks after the second i.v. inoculation and tested by
ELISA against VEE showed a geometric mean titer of
1:17,947. Compared to the first two immunizations, the third
and fourth inoculations were given at a higher dose (5 3 108
IU) and by a different route (i.v.), either or both of which may
have contributed to the appearance of anti-VEE antibody.
However, the presence of this antivector response did not
prevent the fifth immunization, consisting of SIV gp140-VRP
given s.c. in the arm, from boosting the SIV-specific antibody
response (Fig. 2).
In standard assays, none of the sera neutralized the chal-
lenge virus, SIVsm E660, an SIV isolate that is less sensitive
than SIVsm H-4i to neutralization in vitro (unpublished data).
However, anti-SIV E660 neutralizing antibodies were detected
in two of the controls and all vaccinated animals following
challenge (see below).
Cellular immune response. Previous experiments with mice
demonstrated that VEE-based vectors expressing HIV MA/
CA, including the HIV MA/CA-VRP, induced a strong HIV-
specific CTL response (K. W. Brown, I. J. Caley, M. R. Betts,
J. A. Frelinger, and R. E. Johnston, unpublished results) (8).
However, the ability of VEE-based vaccine vectors to induce
CTLs in primates was unknown. PBMCs harvested 3 to 4
weeks following the fourth immunization were tested for the
presence of SIV Gag- and Env-specific CD81 CTLs. Two of
the four vaccinated monkeys showed strong cellular immune
responses to both SIV proteins (Fig. 3A and B), and a third
had a low level of SIV-specific CTLs against either Gag or Env
(Fig. 3C). CD81 T lymphocytes isolated from the fourth mon-
key gave no detectable SIV-specific cellular immune response
(Fig. 3D). This was the same animal (K2F) that showed the
lowest titer of anti-Env antibody by ELISA and no neutralizing
antibody against SIVsm H-4i. Calculation of lytic units (7),
which integrated the dose-response curves shown in Fig. 3, also
showed that two of the vaccinated animals (VW6 and PE9) had
substantial responses to both Gag and Env, while two (WON
and K2F) had much lower responses (Table 1). These CTL
assays were done following one in vitro stimulation and there-
fore do not directly measure precursor frequency. However,
the relative levels of specific lysis given by CD-81 T lympho-
cytes from the four vaccinated macaques likely reflect the rel-
ative number of SIV-specific precursor cells that they each
carried. These findings, in conjunction with the serum antibody
titrations described above, demonstrated that immunization
with the SIV-VRP cocktail activated both humoral and cellular
arms of the immune response, although the responses were not
uniform in all animals. The induction of both antibodies and
CTLs is critical for a lentivirus vaccine, because the correlates
of protection from SIV- or HIV-induced disease have not been
clearly determined (45).
Challenge with pathogenic SIVsm E660. Four weeks after
the final immunization all eight macaques were challenged i.v.
with 50 50% monkey infectious doses (MID50) of the patho-
genic SIVsm E660. This large dose and i.v. route ensured that
disease would be evident in the majority of unvaccinated ma-
caques (24). All of the animals were infected by the challenge
virus, as judged by clinical findings and recovery of SIV from
cultures of PBMCs within the first 2 weeks after challenge
(data not shown). By 4 weeks after challenge, two of the con-
trol macaques (one from the diluent group and one from the
HA-VRP group) were showing clear signs of SIV-induced ill-
ness. At weeks 10 and 11, respectively, these animals were
sacrificed because of generalized wasting, diarrhea, dehydra-
tion, and signs of central nervous system disease. Necropsy
results were consistent with a rapidly progressive disease
course as previously described (25). As expected, SIV-specific
antibodies were not detected either by ELISA or by neutral-
FIG. 2. Titers of anti-SIV antibody in sera of vaccinated and control ma-
caques. Four macaques were inoculated four times with a cocktail of SIV gp160-
VRP and SIV MA/CA-VRP (‚ on the x axis). Control animals were inoculated
with equal doses of HA-VRP or diluent. The four SIV-VRP-immunized mon-
keys received a booster containing gp140-VRP ({ on the x axis), followed by a
final boost of gp140-VRP and MA/CA-VRP (ƒ on the x axis). The time of
challenge is indicated (Œ on the x axis). (A) Sera collected at the indicated times
were tested by ELISA. Vaccinated macaques were VW6 (F), PE9 (■), WON
(), and K2F (Œ). Control macaques were N2P (receiving HA-VRP) (E), N8X
(receiving HA-VRP) (ƒ), N9K (receiving diluent) (h), and W1A (receiving
diluent) (‚). (B) Sera were tested for neutralization against SIVsm H-4i in a
CEM3174 cell killing (cytopathic effect) assay (39). (C) Postchallenge titers
regraphed to show the anamnestic neutralizing antibody responses in vaccinated
animals compared to control animals. In each panel, an asterisk on the y axis
indicates the limit of detection.
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ization assay in these two animals at any time after challenge
(Fig. 2) (26).
The protection from disease conferred by SIV-VRP vacci-
nation was clear from the lack of early mortality and from the
short duration of clinical signs in all members of the vaccinated
group. However, a more precise picture of the patterns of virus
replication in unvaccinated and vaccinated animals was ob-
tained by using the branched-chain DNA assay (Chiron Corp.)
to determine the virus load in the blood (Fig. 4) (46). By this
measure, challenge virus replication was significantly lower in
the monkeys that received the SIV-VRP vaccine. The geomet-
ric mean peak viral load in the vaccinated animals was reduced
by more than 2 orders of magnitude from that in the controls
(geometric mean peak titers of 3.2 3 105 versus 5.4 3 107
genome equivalents per ml of plasma; P , 0.05), and the
highest of the peak viral loads in the vaccinated group was
lower than the lowest of those in the controls.
The vaccinated animals showed a range of abilities to sup-
press challenge virus replication, and the level of suppression
correlated with the relative strength of the immune response
induced by VRP vaccination (Table 1). For example, one of
the vaccinated animals (VW6, the one with a high ELISA
antibody titer, detectable neutralizing antibody, and a strong
CTL response), showed the lowest peak viral load and had
undetectable plasma viral loads from 6 to 40 weeks postchal-
lenge. Except for a sample taken 1 week postchallenge, no
virus replication was detected in cultures of PBMCs taken
from this macaque through week 40 postchallenge. At the
other extreme, the animal without detectable neutralizing an-
tibody or a significant CTL response at the time of challenge
(K2F) had a plasma viral load similar to those of the surviving
unvaccinated controls by 16 weeks postchallenge (Fig. 4). The
immune responses and abilities to suppress challenge virus
replication of the remaining two vaccinated animals fell be-
tween these two extremes.
In the unvaccinated controls, two distinct patterns were ap-
parent after only 8 weeks of infection. One HA-VRP control
and one diluent control showed high viremia by 2 weeks post-
challenge, and their titers increased steadily until they were
euthanized as described above. This pattern of serum viremia
has been observed previously with SIVsm E660 infection of
rhesus macaques (24, 32). The other two unvaccinated animals
were able to reduce challenge virus replication, although their
virus loads remained nearly 3 orders of magnitude above the
limit of detection. At 63 weeks postchallenge, the time at which
the experiment was terminated, all four vaccinated animals and
the two remaining controls were clinically healthy.
A clear anamnestic neutralizing antibody response was seen
in all of the vaccinated animals (Fig. 2C), suggesting that the
VRP vaccine consistently primed a humoral immune response
against SIVsm H-4i. This was true even for the animal (K2F)
that showed an ELISA titer but no neutralizing antibody on
FIG. 3. SIV-specific CD81 CTLs in SIV-VRP-vaccinated macaques. PBMCs
were taken from the four SIV-VRP-immunized monkeys at 3 to 4 weeks after the
fourth inoculation, stimulated in vitro, and tested for lytic activity against autol-
ogous target cells infected with vaccinia virus expressing SIV Gag (F) or SIV Env
(■). Control target cells were infected with vaccinia virus alone (E) or left
uninfected (h). Vaccinated monkeys were VW6 (A), PE9 (B), WON (C), and
K2F (D). Similar results were obtained in two independent assays of PBMCs
from VW6 and PE9.
TABLE 1. Summary of immunological and challenge results
Treatment Macaque Anti-SIVsm H-4ineutralizing antibody titera




specificc Peak Post-acute phase
SIV-VRP VW6 121 85 43 79,210 #1,500
PE9 78 59 53 73,130 #1,500
WON 259 18 14 1,899,000 40,726
K2F #20 16 25 943,500 25,581
HA-VRP N2P #20 NAe NA 42,460,500 44,339,026f
N8X #20 NA NA 6,539,000 126,093
PBS N9K #20 NA NA 499,917,700 1,281,454
W1A #20 NA NA 60,226,300 102,877,164f
a On the day of challenge (Fig. 2B). The limit of detection was 20.
b Targets were infected with vaccinia virus expressing Gag-Pro-Pol (Fig. 3).
c Targets were infected with vaccinia virus expressing Env (Fig. 3).
d Genome equivalents per milliliter of plasma at peak viremia (2 or 3 weeks postchallenge) or geometric mean of two measurements taken during post-acute phase
(6 to 8 weeks postchallenge [Fig. 4]). The limit of detection was 1,500.
e NA, not applicable. PBMCs from control animals could not be stimulated in vitro.
f Early mortality from SIV-induced disease.
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the day of challenge. As this anamnestic neutralizing antibody
response was directed against the vaccine virus and not the
challenge virus, its contribution to the observed protection
against SIVsm E660-induced disease is unclear. Much later, at
16 weeks postchallenge, sera from all surviving animals also
neutralized the challenge virus, SIVsm E660. However, SIVsm
E660-neutralizing activity appeared no sooner in vaccinated
animals than in the two surviving controls.
DISCUSSION
We have described in this report the first trial of a multi-
component VEE-based SIV vaccine in rhesus macaques, in-
cluding a high-dose i.v. challenge with a pathogenic uncloned
stock of SIV. The results of this trial demonstrated the safety
and immunogenicity of SIV-VRP vaccines and also gave a first
measure of their efficacy. All of the vaccinated animals re-
mained healthy at 16 months postchallenge. Two of four con-
trols were euthanized with symptoms of severe SIV infection at
10 and 11 weeks. The mean peak viral load was 2 orders of
magnitude lower in the vaccinated animals than in the controls,
and the mean viral load in the vaccinated animals during the
post-acute phase of infection (6 to 8 weeks postchallenge) (32)
was 750-fold lower. The ability to control SIV replication and
reduce viral load to undetectable levels was closely correlated
with the strongest measurable antibody responses and the
strongest relative anti-SIV CD81 CTL responses. This corre-
lation between protection and the immune response to VRP-
expressed proteins suggests that VRP vaccination was effective
in these individuals. Humoral and cellular immune responses
that are strong enough to give long-term control of virus rep-
lication may be a sufficient goal for an HIV vaccine, in that this
could delay or possibly prevent immune suppression and dis-
ease as well as reduce the rate of transmission.
Optimum route and dose for VRP vaccination. Inoculation
routes and vaccine doses were varied during this trial. Changes
were based on interim immune responses and on data obtained
from parallel studies in the mouse model for VRP vaccination.
In addition, a separate concurrent experiment was performed
with naive macaques to compare different doses of VRP given
s.c. in the arm. In this separate experiment, two rhesus ma-
caques per dose were inoculated with 106, 107, or 108 IU of
HA-VRP and boosted at 5 weeks with an equal amount. Mean
serum antibody titers induced by two inoculations of the 106
dose were 1:2,000 as measured by ELISA or 1:120 by hemag-
glutination inhibition (HAI), similar to those induced by the
higher doses. These titers were comparable to those seen in the
HA-VRP controls described above, in which four vaccinations
by a combination of s.c. (inguinal) and i.v. routes at doses
ranging up to 5 3 108 IU produced mean titers of 1:3,000 (by
ELISA) and 1:120 (by HAI). These preliminary results point to
a likely effective dose (106 IU) and route of vaccination (s.c. in
the arm).
Comparison of alphavirus replicon vector challenge exper-
iments. Replicon vaccine vectors derived from SFV, another
alphavirus, have been tested in two macaque studies. In the
first, pigtailed macaques were vaccinated four times with SFV
replicons expressing PBj14 Env gp160 (40). All of the vacci-
nated animals developed anti-gp160 antibodies detectable by
ELISA but showed no neutralizing antibodies or T-cell prolif-
erative responses. SIV-specific CTLs were not assayed. Upon
challenge with a 100% infectious, 75% fatal dose of SIV-
PBj14-bcl3, three of four controls died, while all four vacci-
nated animals became ill but were protected from acute lethal
disease. Plasma viral loads, reported as 50% tissue culture
infectious doses per milliliter, were 10-fold lower in the vacci-
nated animals than in two controls on their day of death. (The
equivalent differential in the SIV-VRP experiment reported
here, between mean viral loads of the vaccinated animals and
the two controls that died, was greater than 10,000-fold.) Al-
though the SFV replicon vaccine afforded protection from the
acute death syndrome caused by this strain of SIV and a re-
duction in plasma virus load, the relevance of this unique
SIV-macaque model to models of SIV-induced simian AIDS
and HIV-induced human AIDS is uncertain.
In a second SFV replicon vaccine trial, an SFV replicon
expressing HIV-1IIIB gp160 was used in four inoculations of
four cynomolgus macaques (6). Vaccination induced anti-
FIG. 4. Challenge of SIV-VRP-vaccinated and control macaques with SIVsm E660. Monkeys inoculated with either diluent (N9K [h] and W1A [‚]), HA-VRP
(N2P [E] and N8X [ƒ]) or a cocktail of SIV-VRP (MA/CA plus gp160 and MA/CA plus gp140) (VW6 [F], PE9 [■], WON [], and K2F [Œ]) were challenged i.v. with
50 MID50 of SIVsm E660 at 4 weeks following the final booster. Plasma taken at the indicated times was analyzed by the branched-chain DNA assay (46) for
quantitation of SIV genome equivalents. One monkey from the diluent group (W1A) and one from the HA-VRP group (N2P) were euthanized with severe symptoms
of SIV infection at 10 and 11 weeks, respectively. *, limit of detection (1,500 genomes per ml).
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gp160 antibodies, measured by ELISA, in one of four vacci-
nated animals, no neutralizing antibody, and transient T-cell
proliferative responses in two of the four. CTLs were not
assayed. All of the macaques became infected upon challenge
with the chimeric SHIV-4. Three of the vaccinated animals at
1 month postchallenge showed a 30-fold reduction in virus load
(measured by a limiting dilution cocultivation assay) compared
to three controls. This vaccine was less immunogenic than that
used in the first study, possibly due to differences between the
two expressed gp160 molecules. Vaccination did not prevent
infection, but the anamnestic antibody and T-cell proliferative
responses may have modulated the growth of the challenge
virus. However, no correlation could be made between pre-
challenge immune responses and the outcome of the chal-
lenge. This nonpathogenic virus produces only transient vire-
mia, making assessment of efficacy difficult in the absence of
sterilizing immunity.
The SIVsm E660 challenge used in this experiment was a
highly stringent test of efficacy, since an HIV vaccine would not
be required to protect a human against such a large i.v. dose of
HIV. Previously reported primate trials using vaccine vectors
and similar high-dose i.v. challenges with pathogenic SIV did
not prevent infection (5, 24, 34). Results obtained in one of
these studies suggested that an immune response that did not
protect against i.v. challenge was partially protective against an
intrarectal challenge (5). Therefore, the protection afforded by
the SIV-VRP vaccination against a pathogenic i.v. challenge
might be more effective against a less stringent mucosal chal-
lenge. More importantly, a mucosal challenge mimics the most
common route of HIV infection and for this reason will be
included in future trials.
A more consistent immune response and increased protec-
tion may be achieved by one or more improvements in the
VRP vaccine. These could include the incorporation of
the remainder of the gag gene into the MA/CA VRP and the
addition of a Pol-VRP to the cocktail. This would expand the
number of available epitopes and thereby increase the oppor-
tunity for an immune response in members of an outbred
population. Moreover, a measurable Pol-specific CTL re-
sponse has been correlated with lowered viral loads in long-
term survivors of HIV infection (7). The use of a protein
booster also may improve the response to VRP vaccination.
Prime-boost protocols, in which a vaccine vector is followed by
a recombinant protein booster, have been shown to induce a
better immune response than the vector alone against both
SIV and HIV (1, 12). Additional SIV-macaque trials combin-
ing optimum dose and route, added immunogens, and a mu-
cosal challenge will further define the potential of the VRP
vector system as a candidate HIV vaccine.
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